Edition:
United States

Unilife Corp (UNS.AX)

UNS.AX on Australia Stock Exchange

0.04AUD
17 Feb 2017
Change (% chg)

$-0.00 (-4.35%)
Prev Close
$0.05
Open
$0.04
Day's High
$0.04
Day's Low
$0.04
Volume
220,392
Avg. Vol
972,238
52-wk High
$0.26
52-wk Low
$0.04

UNS.AX

Chart for UNS.AX

About

Unilife Corporation is engaged in the designing, development and manufacturing of injectable drug delivery systems. The Company has a portfolio of product platforms, including pre-filled syringes, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems, and other systems for the... (more)
No analyst recommendations are available for UNS.AX.

Overall

Beta: -0.41
Market Cap(Mil.): $49.77
Shares Outstanding(Mil.): 1,088.60
Dividend: --
Yield (%): --

Financials

  UNS.AX Industry Sector
P/E (TTM): -- 34.11 29.39
EPS (TTM): -0.11 -- --
ROI: -120.34 12.43 13.06
ROE: -- 14.41 14.19

BRIEF-Unilife says investigation identifies no material financial loss

* Unilife - on May 8, co announced investigation into violations of policies, procedures, possible violations of laws, regulations by former CEO Alan Shortall

Nov 14 2016

BRIEF-Unilife delays result, investigating possible violations by former CEO

* Unilife - co's 2016 form 10-Q , 2016 form 10-k had been delayed as a result of co's investigation into possible violations of law and regulation by co's former CEO, Alan Shortall Source text for Eikon: Further company coverage:

Nov 10 2016

BRIEF-Unilife Corporation provides business update

* Unilife Corp - Revenue for Q4 of fiscal 2016 was $6.3 million compared to $3.5 million

Nov 02 2016

BRIEF-Unilife Corp implemented cost reduction measures

* Unilife Corp - reduced workforce to approximately 140 employees

Oct 24 2016

BRIEF-Unilife will not be able to file audited financial statements with Australian Securities Exchange by ASX deadline

* Will not be able to file audited financial statements with Australian Securities Exchange by ASX deadline - SEC filing

Sep 29 2016

BRIEF-Unilife Corp announces receipt of delinquency letter from Nasdaq

* Unilife Corporation announces receipt of delinquency letter from nasdaq relating to fiscal 2016 form 10-k Source text for Eikon: Further company coverage:

Sep 23 2016

BRIEF-Biodel enters into an asset purchase and license agreement with Unilife Corp and Unilife Medical Solutions

* On September 2, 2016, co, Unilife Corp and Unilife Medical Solutions Inc entered into an asset purchase and license agreement

Sep 09 2016

More From Around the Web

Earnings vs. Estimates